Met-HeFT meta-analysis
Paziente / Popolazione Intervento / Esposizione Confronto Esito
In patients with heart failure or ischaemic heart disease in studies of metformin, metformin did not reduce clinical outcomes compared with no metformin.
N
2200pazienti
Disegno
Meta-analysis of randomised placebo-controlled metformin trials, presented alongside Met-HeFT: 3 trials in heart failure with reduced ejection fraction (1,077 patients, including Met-HeFT) and 4 trials in established ischaemic heart disease (1,123 patients); presenter Anders Hostrup Larsen, Goedstrup Hospital, Herning, Denmark
Esito
—
Rilevanza
3Complementare — contesto, non conoscenza imprescindibile.
RisultatoPooling the randomised evidence in heart failure and in ischaemic heart disease reached the same conclusion as the trial: no significant protection against cardiovascular outcomes with metformin.
Presented at ESC Congress 2026, Hot Line 6, 30 August.
Discussione e critica
The companion to Met-HeFT, and it lands in the same place: across the randomised evidence in heart failure and in ischaemic heart disease, metformin does not protect against cardiovascular events. Read with the trial, the observational signal that made metformin a cardiovascular drug looks like confounding by who gets prescribed it. Numbers beyond the direction were not in the material released with the presentation; this entry will carry them when the publication appears.